Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Cathepsin D as a potential prognostic marker for lung adenocarcinoma.

Mimae T, Tsuta K, Maeshima AM, Okada M, Asamura H, Kondo T, Tsuda H.

Pathol Res Pract. 2012 Sep 15;208(9):534-40. doi: 10.1016/j.prp.2012.05.020. Epub 2012 Jul 21.

PMID:
22824147
3.

Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma.

Paik JH, Choi CM, Kim H, Jang SJ, Choe G, Kim DK, Kim HJ, Yoon H, Lee CT, Jheon S, Choe JY, Chung JH.

Lung Cancer. 2012 Jun;76(3):403-9. doi: 10.1016/j.lungcan.2011.11.008. Epub 2011 Nov 30.

PMID:
22129856
4.

Napsin A is an independent prognostic factor in surgically resected adenocarcinoma of the lung.

Lee JG, Kim S, Shim HS.

Lung Cancer. 2012 Jul;77(1):156-61. doi: 10.1016/j.lungcan.2012.02.013. Epub 2012 Mar 13.

PMID:
22418245
5.

Expression of cathepsin D in transitional cell bladder tumours.

Lipponen PK.

J Pathol. 1996 Jan;178(1):59-64.

PMID:
8778318
6.

Correlation between cathepsin D expression and p53 protein nuclear accumulation in oesophageal squamous cell carcinoma.

Ikeguchi M, Sakatani T, Ueta T, Fukuda K, Oka S, Hisamitsu K, Yamaguchi K, Tsujitani S, Kaibara N.

J Clin Pathol. 2002 Feb;55(2):121-6.

7.

Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.

Park HS, Lee JK, Kim DW, Kulig K, Kim TM, Lee SH, Jeon YK, Chung DH, Heo DS.

Lung Cancer. 2012 Aug;77(2):288-92. doi: 10.1016/j.lungcan.2012.03.004. Epub 2012 Mar 31.

PMID:
22465695
8.

Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas.

Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi K, Iwakawa R, Furuta K, Tsuta K, Shibata T, Yamamoto S, Watanabe S, Sakamoto H, Kumamoto K, Takenoshita S, Gotoh N, Mizuno H, Sarai A, Kawano S, Yamaguchi R, Miyano S, Yokota J.

Cancer Res. 2012 Jan 1;72(1):100-11. doi: 10.1158/0008-5472.CAN-11-1403. Epub 2011 Nov 11.

9.

ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.

Lee KH, Min HS, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Kim YT, Kim TY, Heo DS, Bang YJ, Sung SW, Kim JH.

Lung Cancer. 2008 Jun;60(3):401-7. Epub 2007 Nov 26.

PMID:
18036700
10.

Toward personalized medicine of lung cancer: response to nontargeted therapy in invasive pulmonary adenocarcinoma as a function of tumor cell differentiation.

Hartel PH, Hartel JV, Fanburg-Smith JC, Gilmore RW, Fleming D, Barnett S, Mudry R, Parker JE.

Int J Surg Pathol. 2013 Jun;21(3):224-8. doi: 10.1177/1066896913486694. Epub 2013 May 1.

PMID:
23637254
11.

Cathepsin K is selectively expressed in the stroma of lung adenocarcinoma but not in bronchioloalveolar carcinoma. A useful marker of invasive growth.

Rapa I, Volante M, Cappia S, Rosas R, Scagliotti GV, Papotti M.

Am J Clin Pathol. 2006 Jun;125(6):847-54.

PMID:
16690483
12.

[The research of clinical pathological features of ALK positive lung cancer in 525 patients and the discussion of detection methods].

Zhu X, Li H, Cao B, Liu C, Liang L, Wang Y, You J, Gao F, Ma X, Liu Y, Wang H, Zhang Y, Chen J, Zhang B.

Zhongguo Fei Ai Za Zhi. 2014 Mar;17(3):226-32. doi: 10.3779/j.issn.1009-3419.2014.03.08. Chinese.

13.

Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.

Wang KL, Wu TT, Choi IS, Wang H, Resetkova E, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Albarracin CT.

Cancer. 2007 Feb 15;109(4):658-67. Erratum in: Cancer. 2009 May 1;115(9):2024. Reseetkova, Erika [corrected to Resetkova, Erika].

14.

Comparison of FISH, PCR, and immunohistochemistry in assessing EGFR status in lung adenocarcinoma and correlation with clinicopathologic features.

El-Zammar OA, Zhang S, Katzenstein AL.

Diagn Mol Pathol. 2009 Sep;18(3):133-7. doi: 10.1097/PDM.0b013e3181857ea9.

PMID:
19704257
15.

Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density.

Lösch A, Schindl M, Kohlberger P, Lahodny J, Breitenecker G, Horvat R, Birner P.

Gynecol Oncol. 2004 Feb;92(2):545-52.

PMID:
14766246
16.

Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component.

Yoshida A, Tsuta K, Watanabe S, Sekine I, Fukayama M, Tsuda H, Furuta K, Shibata T.

Lung Cancer. 2011 Jun;72(3):309-15. doi: 10.1016/j.lungcan.2010.09.013. Epub 2010 Oct 30.

PMID:
21036415
17.

RET finger protein expression is associated with prognosis in lung cancer with epidermal growth factor receptor mutations.

Iwakoshi A, Murakumo Y, Kato T, Kitamura A, Mii S, Saito S, Yatabe Y, Takahashi M.

Pathol Int. 2012 May;62(5):324-30. doi: 10.1111/j.1440-1827.2012.02797.x. Epub 2012 Mar 27.

PMID:
22524660
18.

An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas.

Dickinson AJ, Fox SB, Newcomb PV, Persad RA, Sibley GN, Harris AL.

J Urol. 1995 Jul;154(1):237-41.

PMID:
7776437
19.

Significance of estrogen receptors and cathepsin D tissue detection in gastric adenocarcinoma.

Theodoropoulos GE, Lazaris AC, Panoussopoulos D, Davaris P, Golematis BC.

J Surg Oncol. 1995 Mar;58(3):176-83.

PMID:
7898114
20.

Clinicopathological significance of cathepsin D expression in gastric adenocarcinoma.

Ikeguchi M, Fukuda K, Oka S, Yamaguchi K, Hisamitsu K, Tsujitani S, Sakatani T, Ueda T, Kaibara N.

Oncology. 2001;61(1):71-8.

PMID:
11474252

Supplemental Content

Support Center